<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00336739</url>
  </required_header>
  <id_info>
    <org_study_id>2455</org_study_id>
    <nct_id>NCT00336739</nct_id>
  </id_info>
  <brief_title>The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether cinacalcet will increase gastric acid&#xD;
      secretion in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The calcium sensing receptor (CaSR) was originally found on parathyroid and renal cells and&#xD;
      more recently it has been identified on cells that regulate gastric acid secretion (G cells&#xD;
      and parietal cells). However, its role in regulating acid secretion in humans is completely&#xD;
      unknown and is of potential importance because an acid environment in the stomach enhances&#xD;
      intestinal calcium absorption. In this pilot project, we will stimulate the CaSR with a&#xD;
      CaSR-agonist called cinacalcet. Our hypothesis is that activation of the CaSR will in turn&#xD;
      increase gastric acid production in healthy volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare change in gastric acid output in response to an 11-day course of daily cinacalcet or placebo in subjects on a fixed protein metabolic diet.</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare serum gastrin levels in subjects before and after an 11-day course of cinacalcet or placebo and on a fixed protein metabolic diet.</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare 24-hour urinary calcium excretion before and after an 11-day course of cinacalcet or placebo and on a fixed protein metabolic diet.</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare serum IGF-1 levels before and after an 11-day course of cinacalcet or placebo and on a fixed protein metabolic diet.</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare change in urinary magnesium excretion in response to an 11-day course of daily cinacalcet or placebo in subjects on a fixed protein metabolic diet.</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cinacalcet</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy ambulatory men and postmenopausal women&#xD;
&#xD;
          -  Age 45 to 70&#xD;
&#xD;
          -  Avoid alcohol, antacids, H2 blockers, proton pump inhibitors, or antihistamines during&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ionized Ca++ level &lt;4.39 mg/dl or &gt;5.02 mg/dl (normal reference range 4.18- 5.02).&#xD;
&#xD;
          -  24-hour UCa++ excretion &gt;350 mg.&#xD;
&#xD;
          -  Cr &gt;1.3.&#xD;
&#xD;
          -  AST/ALT values &gt;10% beyond reference range.&#xD;
&#xD;
          -  Hgb level &lt;11.7 g/dl in women and &lt;13.2 g/dl in men.&#xD;
&#xD;
          -  MCV level &gt;102 UM3.&#xD;
&#xD;
          -  Basal acid output &gt;5 mEq/h in men and &gt;3.8 mEq/h in women.&#xD;
&#xD;
          -  Basal acid output &lt;1 mEq/h in men and &lt;0.2 mEq/h in women.&#xD;
&#xD;
          -  Age &lt;45 or &gt;70.&#xD;
&#xD;
          -  Premenopausal or &lt;1 year post-menopause.&#xD;
&#xD;
          -  Individuals following vegan diets.&#xD;
&#xD;
          -  Current EtOH abuse.&#xD;
&#xD;
          -  Lidocaine allergy. Medications&#xD;
&#xD;
          -  Antacids&#xD;
&#xD;
          -  H2 blockers&#xD;
&#xD;
          -  Proton pump inhibitors&#xD;
&#xD;
          -  Carafate&#xD;
&#xD;
          -  Anticholinergic agents (i.e. TCA)&#xD;
&#xD;
          -  Cholinergic agents&#xD;
&#xD;
          -  Antihistamines in the last 3 weeks&#xD;
&#xD;
          -  Cogentin&#xD;
&#xD;
          -  Adrenergic blockers&#xD;
&#xD;
          -  Thiazide diuretics&#xD;
&#xD;
          -  Antiplatelet drugs&#xD;
&#xD;
          -  Oral and Inhaled Glucocorticoids&#xD;
&#xD;
          -  Bisphosphonates&#xD;
&#xD;
          -  Raloxifene, Tamoxifen&#xD;
&#xD;
          -  Tobacco&#xD;
&#xD;
          -  EtOH during study&#xD;
&#xD;
          -  rPTH&#xD;
&#xD;
          -  Calcitonin&#xD;
&#xD;
          -  Ketoconazole/Itraconazole&#xD;
&#xD;
          -  Calcitriol&#xD;
&#xD;
          -  Paricalcitol&#xD;
&#xD;
          -  Drisdol, Ergocalciferol&#xD;
&#xD;
          -  Phosphate binders&#xD;
&#xD;
          -  Anticoagulant&#xD;
&#xD;
          -  Erythromycin&#xD;
&#xD;
          -  Hormone replacement therapy except vaginal estrogen creams&#xD;
&#xD;
        Exclusion Diseases&#xD;
&#xD;
          -  Achlorhydria&#xD;
&#xD;
          -  Pernicious anemia&#xD;
&#xD;
          -  Zollinger Ellison syndrome&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Esophageal strictures or motility problems&#xD;
&#xD;
          -  History of a GI bleed&#xD;
&#xD;
          -  Prior upper GI surgery&#xD;
&#xD;
          -  Malabsorption&#xD;
&#xD;
          -  History of GI malignancy&#xD;
&#xD;
          -  GERD, gastritis, duodenitis&#xD;
&#xD;
          -  Active peptic ulcer disease&#xD;
&#xD;
          -  Gallbladder disease&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Pancreatitis&#xD;
&#xD;
          -  Current kidney stone&#xD;
&#xD;
          -  Renal disease&#xD;
&#xD;
          -  Current hypoparathyroidism or hyperparathyroidism&#xD;
&#xD;
          -  Moderate to Severe coronary artery disease&#xD;
&#xD;
          -  Aortic aneurysm&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  Current Arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bess Dawson-Hughes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Human Nutrition Research Center on Aging at Tufts University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Human Nutrition Research Center on Aging at Tufts University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>June 12, 2006</study_first_submitted>
  <study_first_submitted_qc>June 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2006</study_first_posted>
  <last_update_submitted>July 20, 2007</last_update_submitted>
  <last_update_submitted_qc>July 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2007</last_update_posted>
  <keyword>Gastric acidity determination</keyword>
  <keyword>Calcium sensing receptor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cinacalcet</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

